Mesoblast Limited announced that U.S. FDA has informed the company that following additional consideration the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application (BLA) for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD). Mesoblast intends to file the resubmission during the next quarter, seeking to address all remaining product characterization issues.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.085 AUD | +1.40% | +18.58% | +250.00% |
Apr. 01 | ADRs End Higher; Connect Biopharma Climbs 26% | DJ |
Mar. 28 | ADRs End Lower; NuCana Slides 15% | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+250.00% | 799M | |
+23.59% | 48.09B | |
+46.90% | 40.62B | |
-2.72% | 40.43B | |
-6.20% | 28.36B | |
+8.38% | 24.89B | |
-20.31% | 19.01B | |
+28.93% | 12.09B | |
+0.01% | 11.88B | |
-1.01% | 11.8B |
- Stock Market
- Equities
- MSB Stock
- News Mesoblast Limited
- United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease